Source Paper
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Joshua S. Kaplan, Nephi Stella, William A. Catterall, Ruth E. Westenbroek
Proceedings of the National Academy of Sciences • 2017
View Abstract
Significance Medicinal cannabis use is booming despite limited preclinical evidence and mechanistic insight. Recent clinical trials of cannabidiol (CBD) in Dravet syndrome (DS) support its clinical efficacy for reduction of seizure frequency and invite study of its benefits for additional DS symptoms. We demonstrate here that treatment with CBD is beneficial for seizure frequency, duration, and severity and for autistic-like social deficits in a mouse model of DS. CBD rescue of DS symptoms is associated with increased inhibitory neurotransmission, potentially mediated by antagonism of the lipid-activated G protein-coupled receptor GPR55. These studies lend critical support for treatment of seizures in DS with CBD, extend the scope of CBD treatment to autistic-like behaviors, and provide initial mechanistic insights into CBD’s therapeutic actions.
Spontaneous Seizure Monitoring
Objective: Quantification of the frequency of spontaneous seizures occurring in Dravet syndrome mice to assess the effects of cannabidiol (CBD) treatment on seizure phenotype
This is a Spontaneous Seizure Monitoring protocol using mouse as the model organism. The procedure involves 1 procedural steps. Extracted from a 2017 paper published in Proceedings of the National Academy of Sciences.
Model and subjects
mouse • Dravet syndrome mouse model (Scn1a mutation) • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Spontaneous Seizure Monitoring
Primary readouts
- Frequency of spontaneous seizures
- Duration of seizures
- Severity of seizures
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Spontaneous Seizure Monitoring
Monitor and quantify the frequency of spontaneous seizures occurring in Dravet syndrome mice during the experimental period
Note: The frequency of spontaneous seizures was measured as a primary outcome to assess CBD treatment effects
View evidence from paper
“the frequency of spontaneous seizures were substantially decreased”